



OpGen Corporate Overview

October 8, 2021




Forward Looking Statements Disclaimer

This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will” and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen’s control, and that may cause results to differ materially from expectations.

Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the realization of expected synergies from our business combination transaction with Curetis GmbH, the successful integration of our company with the operations and business of Curetis GmbH and its subsidiaries and the implementation of the combined company’s strategic and business goals and objectives, the impact of COVID-19 on our operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the ability to comply with the complexities of operating a global business, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Overview

Striving to innovate molecular microbiology



OpGen's combined portfolio

Synergistic products and capabilities

Unyvero Platform & Syndromic Tests



FDA-cleared LRT & LRT BAL for lower respiratory tract infections

5 CE-IVD tests

Unyvero A30 RQ platform in advanced stages of development

Acuitas Panel & Lighthouse



FDA-cleared Acuitas AMR Gene Panel for Isolates

Enhances targeted antibiotic decision making

Lighthouse knowledge base deployed for public health use


Global Commercial Presence



Direct sales and marketing in the U.S.

EMEA, APAC, Latin America and China distribution with partners

Ares Genetics NGS & Bioninformatics



AI-powered AMR prediction combining ARESdb with NGS

Strategic partnerships and collaborations with globally leading IVD & pharma companies

OpGen's strategic positioning and benefits



Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection



Proprietary molecular diagnostic tests and platforms



Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics




Global commercial channel capabilities & partners



Financial leverage, operational synergies, and positive growth-driven business outlook

Unmet clinical needs and large available market opportunities

U.S. and European markets addressed through hospital-focused sales channels



■ Pneumonia (HPN / LRT / LRT BAL)

■ Urinary Tract Infections (UTI)

■ Implant and Tissue Infections (ITI) / Invasive Joint Infections (IJI)

■ Blood Culture (BCU)

■ Intra-Abdominal Infections (IAI)

The current Unyvero portfolio and pipeline of cartridges according to management estimates target about 9 million patients annually in EU and U.S. with additional upside in Asia / Pacific and ROW markets.

OpGen's strategic positioning and benefits



Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection



Proprietary molecular diagnostic tests and platforms



Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics



Global commercial channel capabilities & partners



Financial leverage, operational synergies, and positive growth-driven business outlook

Sample-to-answer high-throughput testing capabilities


Innovating molecular microbiology through proprietary platforms and content

Rapid low-plex to high-plex MDx diagnostics
Broad range of sample types and indications

unyvero



Unyvero A50
High-Plex PCR



Unyvero A30 RQ*
Low- to Mid-Plex qPCR

Acuitas
AMR Gene Panel



Acuitas AMR Gene Panel
Real-time PCR**

Proprietary PCR & NGS applications based on
leading AI-powered AMR knowledgebases

Acuitas
Lighthouse



Acuitas Lighthouse
MDx Content

ares genetics




ARES Genetics
ARESdb & NGS Applications

*Unyvero A30 RQ Analyzer in development, latest design concept; final product may differ.

**OpGen Qualified Applied Biosystems™ QuantStudio 5 Real-Time PCR System for use with the Acuitas AMR Gene Panel for real-time multiplex reaction and detection.

Broad Unyvero cartridge portfolio







unyvero



*Unyvero LRT / LRT BAL are FDA-cleared; all other products are CE-IVD marked or in development.

Unique and differentiated syndromic panels



Cartridge		Indication area	Number of targets covered	Sample types	Clearance status
HPN*		Severe cases of Pneumonia	48 targets*** pathogens (29) and antibiotic resistance markers (19)	Sputum, broncho-alveolar lavage, tracheal aspirate	CE-IVD marked Singapore (HAS) Thailand Malaysia
LRT & LRT BAL		Lower Respiratory Tract Infections	LRT (LRT BAL): 46 (47) targets**** pathogens 36 (37) and antibiotic resistance markers 10 (10)	LRT: Tracheal aspirates LRT BAL: Bronchoalveolar Lavage (BAL)	LRT: FDA cleared (4/2018) LRT BAL: FDA cleared (12/2019)
ITI		Severe cases of Implant and Tissue Infections	102 targets pathogens (85) and antibiotic resistance markers (17)	Sonication fluid, swabs, striche, tissue, pus, aspirate/ exudate, etc.	CE-IVD marked
UTI		Severe cases of Urinary Tract Infections	103 targets pathogens (88) and antibiotic resistance markers (15)	Midstream urine, suprapubic aspiration, tissue	CE-IVD marked
BCU**		Bloodstream infections	103 targets pathogens (86) and antibiotic resistance markers (17)	Positively flagged blood cultures	CE-IVD marked Singapore (HAS) Thailand
IAI		Severe Intra-Abdominal Infections	130 targets pathogens (105), toxins (3) and antibiotic resistance markers (22)	Paracentesis fluids, biliary fluids, peritoneal fluids, drainage fluids, retroperitoneal fluids, pus, swabs, samples from positively flagged blood culture bottles inoculated with other fluids than blood (IAI fluids such as ascites)	CE-IVD marked

*HPN: Hospitalized Pneumonia **BCU: Blood Culture Application
 ***Difference between HPN and LRT (BAL) due to different reporting
 requirements between CE-IVD and U.S. FDA-cleared products.

Current U.S. product offerings



Unyvero LRT & LRT BAL



Sample-to-answer
Results under 5 hrs
2 min hands-on time



Direct from native specimen
FDA-cleared for bronchoalveolar lavage (BAL, mini-BAL) and tracheal aspirates
Multiplex PCR with array detection



Detects the most clinically relevant pathogens (incl. atypicals) &
antibiotic resistance markers associated with lower respiratory tract infections
including pneumonia



Broadest carbapenemase resistance coverage
The only FDA-cleared panel that detects *Pneumocystis jirovecii*
Identifies difficult to culture *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Legionella pneumophila*

**Critical results for
life-saving treatment
decisions**

Current U.S. product offerings

FDA-cleared AMR Gene Panel allows testing for a comprehensive panel of 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogens

**Detects AMR Genes in Most
Deadly Superbugs**




E. coli, *K. pneumoniae*, *P. mirabilis*, *P. aeruginosa*,
E. faecalis, as well as in several others:
C. freundii complex, *C. braakii*, *C. freundii*, *C. koseri*,
C. werkmanii, *C. youngae*, *E. cloacae* complex,
E. asburiae, *C. cloacae*, *E. hormaechei*, *E. kobei*,
E. ludwigii, *K. aerogenes*, *K. michiganensis*,
K. oxytoca, *K. quasi-pneumoniae*, *K. variicola*,
M. morgani, *P. rettgeri*, *P. stuartii*, *R. ornithinolytica*,
R. planticola, *S. marcescens*

Identifies



Broad panel of resistance genes
Spanning 9 antibiotic classes
Valuable diagnostic tool that informs about
potential AMR patterns early and supports
appropriate antibiotic treatment decisions

Results under 3 hrs



Directly from pure isolated colonies
FDA clearance decision pending
Multiplex PCR results in under 3 hours

Unyvero A30 RQ

Rapid sample-to-answer testing platform: batch of pre-series release analyzers now in final V&V testing following achievement of key milestone

Key Design Features


- Fully integrated, closed, sample-to-answer MDx platform
- Universal real-time PCR technology for low- to mid-plex testing
- Flexible cartridge fluidics for numerous chemistries and assay formats
- Fast turn-around time from ~30 to ~90 minutes
- Light-weight, stackable benchtop design with small footprint
- Modular and scalable from 1 to 8 cartridge slots
- Designed for ease-of-use and flexible deployment in labs and near-patient settings
- Attractive COGS for instruments and reagents

Platform available for partnering



Development Status

- Demonstrated clinical proof of concept from sample to answer with various assays including SARS CoV-2, Flu-A / Flu-B and RSV
- Manufacturing aspects fully specified and in development or implementation phase
- Curetis makes Unyvero A30 RQ platform available for partnering
- V&V testing for mechanical and electrical aspects as well as life-time testing ongoing



red curve:
Influenza B, Ct = 21

orange curve:
Influenza A, Ct = 25.5

blue curve:
SARS-CoV2, Ct = 25

black curve:
RSV, Ct = 36

* Unyvero A30 RQ Analyzer in development, latest design concept; final product may differ.

OpGen's strategic positioning and benefits



Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection



Proprietary molecular diagnostic tests and platforms



Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics





Global commercial channel capabilities & partners



Financial leverage, operational synergies, and positive growth-driven business outlook

Ares Genetics and ARESdb*

Bioinformatics powerhouse with industry-leading proprietary AI-powered AMR knowledgebase for molecular microbiology



* In development; For Research Use Only.
Not for use in diagnostic procedures.

Global ARESdb

- Unique knowledgebase on antibiotic resistance markers building partly on Siemens microbiology strain collection
- Demonstrated up to > 99% accuracy for antibiotic susceptibility prediction in evaluation studies
- Based on > 55,000 pathogens and associated resistance data for > 100 antibiotics

First RUO applications launched

- Through NGS service laboratory and cloud platform

Partners and customers include

- Globally leading IVD & pharma companies and national agency
- Amended Qiagen RUO partnership to global non-exclusive
- Recently further expanded the Sandoz collaboration
- Recently added partnerships with UPMC as well as a major U.S. CRO and CLIA lab

OpGen's strategic positioning and benefits



Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection



Proprietary molecular diagnostic tests and platforms



Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics




Global commercial channel capabilities & partners



Financial leverage, operational synergies, and positive growth-driven business outlook

Dual commercial model

Direct in USA – Distribution in EMEA, China and Rest of World




Expanding global commercial reach through direct sales in U.S. and via global distributors

- Direct sales in the U.S.
- European distribution through Menarini Diagnostics
- China distribution through Beijing Clear Biotech
- Distributors covering ~40 countries in EU, ME, LATAM, and Asia
- Exited our FISH products business
- Reduced number of distributors post FISH business exit in 2021

Pan-European distribution via Menarini

Currently 11 EU countries; option to expand relationship to further markets



Menarini Diagnostics & Curetis Collaboration

- Covers entire Unyvero A50 product line
- Currently covered countries:
BE, CH, DE, ES, FR, IT, LU, NL, PT, UK, GR
- Option to expand relationship to further countries



OpGen's strategic positioning and benefits



Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection



Proprietary molecular diagnostic tests and platforms



Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics



Global commercial channel capabilities & partners



Financial leverage, operational synergies, and positive growth-driven business outlook

Financial considerations



Proforma combined revenue

- FY 2018 revenues of \$ 4.5 million
- FY 2019 revenues of \$ 6.0 million
- FY 2020 revenues of \$ 5.2 million



Reported revenue

- Q3 2021 revenues of \$ 1.2 million
- Exit from FISH business and non-recurring IVD partnering revenue from Ares completed R&D project in 2020 as well as growing Unyvero products and lab services testing revenues
- No revenue guidance for 2021 at this time due to COVID-19 situation



Cash position

- Strong cash position: \$ 25.4 million as of 9/30/2021
- Raised \$ 25.0 million in Registered Direct with single U.S. healthcare-focused institutional investor in February 2021
- Executed warrant exercise and exchange deal for \$ 9.7 million gross proceeds in March 2021
- Total cash raised in FY 2020 and 2021 to date approximately \$ 70 million
- S-3 universal shelf filed and effective for up to \$ 150 million



Capital structure – shares outstanding

- Common Stock ~38.3 million shares (as of 9/30/2021)
- Common Warrants ~8.7 million (warrants have avg. exercise price of \$ 3.40)
- Equity Awards ~2.3 million
- Fully Diluted Shares Outstanding ~49.3 million shares

Operations

Headquartered in the U.S. with global operations

Our Facilities

Corporate HQ and FDA registered R&D / manufacturing facility in Rockville, Maryland, USA

- Moved to new Rockville, MD facility in Q2-2021 (~ **10,000 sq. ft.**)
- Optimized layout and operating efficiency at > \$600k p.a. net savings

17,000 sq. ft. FDA registered R&D, operations and G&A facility in Holzgerlingen, southern Germany

17,000 sq. ft. FDA registered manufacturing facility in Bodelshausen, southern Germany

7,000 sq. ft. Bioinformatics and NGS lab facility in Vienna, Austria

A Global Team



OpGen Executive Leadership Team and Board

Team has decades of experience in precision medicine, molecular diagnostics and capital markets

Finalized CFO search; announcement expected to follow formal appointment

Leadership Team



Oliver Schacht, Ph.D.
President & Chief Executive Officer



Johannes (Jan) Bacher
Chief Operating Officer,
Managing Director, Curetis



Arne Materna
Managing Director & CEO,
Ares Genetics



Faranak Atrzadeh
Chief Marketing &
Scientific Affairs Officer

Board Members



William (Bill) Rhodes (Chairman)



Prabhavathi (Prabha) Fernandes, Ph.D.



Don Elsey



Mario Crovetto



Oliver Schacht, Ph.D. (President & CEO)

Recent news flow

OpGen recently announced several key updates and milestones

- OpGen receives FDA 510(k) clearance for Acuitas AMR Gene Panel
- OpGen initiates clinical trial for Unyvero Urinary Tract Infection Panel
- OpGen announces data from prospective randomized controlled multicenter clinical study using the Unyvero HPN panel for hospitalized patients with suspicion of pneumonia
- OpGen reports Q2-2021 earnings and provides business update
- OpGen files S-3 universal shelf for up to \$ 150 million
- OpGen achieves key milestone in Unyvero A30 RQ development program
- OpGen announces prospective clinical data from Unyvero LRT BAL and data on Acuitas AMR Gene Panel for Isolates
- OpGen subsidiary Ares Genetics presents R&D pipeline update with robust performance on nanopore sequencing
- OpGen group company Ares Genetics further extends collaboration with Sandoz
- OpGen raises \$ 9.7 million gross proceeds in warrant exercise and exchange
- OpGen wins Chinese NMPA approval for the Curetis Unyvero System

Upcoming milestones, news flow & catalysts

Unyvero & Acuitas rapid molecular tests

- Commercial launch of Acuitas AMR Gene Panel in the U.S.
- China NMPA requesting supplementary clinical data to be generated in China (est. 600 samples) for submission and potential future approval for pneumonia cartridge and subsequent commercial launch
- Clinical trial updates and regulatory submissions for Unyvero UTI and IJI products
- Unyvero A30 RQ further development milestones and partnering opportunities

Ares Genetics

- Several upcoming commercial launches of services and solutions
- Potential partnering / licensing opportunities
- Clinical data and publications

Contact info

OpGen Inc. (Global HQ)

9717 Key West Avenue, Suite 100
Rockville, MD 20850 USA
+1 301.869.9683

InvestorRelations@opgen.com

Curetis GmbH

Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
+49 (0)7031 49195-10

contact@curetis.com

Ares Genetics GmbH

Karl-Farkas-Gasse 18
1030 Wien, Austria
+43 (0)1 361 8880 10

contact@ares-genetics.com



Thank You!

